DCP
GENB

Davern Capital Partners’s Generate Biomedicines GENB Stock Holding History

Davern Capital Partners’s Portfolio GENB Stock Details GENB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$13.9M Buy
824,679
+232,879
+39% +$3.17M 2.37% 13
2026
Q1 		$7.4M Buy
+591,800
New +$7.23M 2.03% 14

Other funds holding GENB

FP
Flagship Pioneering Cambridge, Massachusetts $1.54B AUM 86.39% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
HP
Harbourvest Partners Boston, Massachusetts $170M AUM 34.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Davern Capital Partners's GENB Position: Q2 2026 in Review

Davern Capital Partners increased its Generate Biomedicines (GENB) stake by 39% in Q2 2026, buying an estimated $3.17M and bringing the position to 824,679 shares worth $13.9M. The position accounts for 2.37% of the portfolio, ranked #13.

Davern Capital Partners first reported a position in GENB in Q1 2026 and has held it in 2 quarters since. 86 funds tracked by Wall St. Rank hold GENB as of Q2 2026.

  • Davern Capital Partners held 824,679 shares of Generate Biomedicines worth $13.9M as of Q2 2026.
  • Davern Capital Partners bought 232,879 Generate Biomedicines shares in Q2 2026, an estimated $3.17M.
  • Generate Biomedicines made up 2.37% of Davern Capital Partners's portfolio in Q2 2026, its #13 holding.
  • Davern Capital Partners first reported a position in Generate Biomedicines in Q1 2026 and has held it in 2 quarters since.
  • 86 funds tracked by Wall St. Rank held Generate Biomedicines as of Q2 2026.

Based on Davern Capital Partners's 13F filing for Q2 2026, filed 13 Aug 2026.